Aptamer Group deserve more attention 

Aptamer Group (LSE: APTA) are unchanged at 0.325p with a £11.7m mkt cap after reporting finals to June 2026 showing significant commercial traction. Over the last three months, the sales pipeline increased 46% from the end of June to £7.0m in September. Revenue for the FY June 26 improved 28% to £1.5m and the EBITDA loss marginally rose to £2.3m from £2.2m, as administration expenses increased to £3.2m from £2.9m as a result of the increased activity.  Aptamer is strategically focused on by targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver....

Latest News

More Articles Like This